The business announced last month that its partner Serum Institute of India will manufacture the first doses of the vaccine. Novavax's injection, which is now available in over 40 countries, is a more traditional sort of vaccination that employs technology that has been used to treat illnesses such as influenza for decades. Novavax is hoping to gain a foothold among the approximately 27 million unvaccinated adults in the United States, particularly those who do not want to receive a vaccine like the Pfizer/BioNTech or Moderna Inc shots, which are based on ground-breaking messenger RNA (mRNA) technology.

This news could not find a better moment to come out, as Israel study reported that 4th dose of vaccine lowered the death rate for 72% among elderlies.

Movement of Novavax in the last five years. (Source: Trading Economics)

Sources:

https://tradingeconomics.com/nvax:us

https://www.timesofisrael.com/major-israeli-study-elderlys-covid-death-slashed-by-72-after-4th-vaccine/

https://www.investing.com/news/stock-market-news/us-secures-32-million-doses-of-novavax-covid-vaccine-2845954

https://www.reuters.com/business/healthcare-pharmaceuticals/us-secures-32-mln-doses-novavax-covid-vaccine-2022-07-11/

https://www.nytimes.com/2022/07/11/science/novavax-covid-vaccine.html